Schneider L S, Olin J T
Department of Psychiatry, University of Southern California School of Medicine, Los Angeles.
Arch Neurol. 1994 Aug;51(8):787-98. doi: 10.1001/archneur.1994.00540200063018.
To assess the overall effect of Hydergine (a combination drug called ergoloid mesylates) on patients with possible dementia and to investigate potential moderators of an effect.
MEDLINE, EMBASE, and two proprietary databases were searched for reports of clinical trials.
Included were randomized, placebo-controlled, double-blind, parallel-group trials in subjects with symptoms consistent with dementia performed with specified outcome instruments and sufficient statistical information to calculate effect sizes. Forty-seven (31%) of 151 trials reviewed met selection criteria.
Potential moderating variables were extracted from each trial: sample size, inpatient-outpatient status, trial duration, age, gender, medication dose, publication year, and diagnostic grouping. Outcome measures were extracted with their associated statistics.
The overall combined treatment effects ("adjusted d") for three types of outcome measures were calculated. Overall, Hydergine was more effective than placebo as assessed by comprehensive ratings (d = 0.47; 95% confidence interval [CI], 0.38 to 0.56; P = .0001), clinical global ratings (d = 0.56; 95% CI, 0.44 to 0.68; P = .0001), and combined neuropsychological measures (d = 0.27; 95% CI, 0.22 to 0.32; P = .0001). Inpatient status, daily doses of 4 mg or more, and vascular dementia were generally associated with larger effects. The effect in patients with possible Alzheimer's dementia was significant only for combined neuropsychological measures in five trials (d = 0.30; 95% CI, 0.16 to 0.44; P = .0001; and with a dose-response, P = .001).
Overall, ergoloid mesylates were more effective than placebo. However, the effect in patients with possible Alzheimer's dementia was very modest at best. The dose-response relation suggests that potentially effective doses may be higher than the currently approved. The circumstances of the efficacy of Hydergine remain inadequately defined.
评估喜得镇(一种名为甲磺酸双氢麦角毒碱的复方药物)对可能患有痴呆症患者的总体疗效,并探究疗效的潜在调节因素。
检索MEDLINE、EMBASE和两个专业数据库以获取临床试验报告。
纳入的研究为在有痴呆症相关症状的受试者中开展的随机、安慰剂对照、双盲、平行组试验,试验使用了特定的结局指标并具备足够的统计信息以计算效应量。在审查的151项试验中,有47项(31%)符合入选标准。
从每项试验中提取潜在的调节变量:样本量、住院/门诊状态、试验持续时间、年龄、性别、药物剂量、发表年份和诊断分组。提取结局指标及其相关统计数据。
计算了三种类型结局指标的总体联合治疗效应(“校正d值”)。总体而言,根据综合评分(d = 0.47;95%置信区间[CI],0.38至0.56;P = 0.0001)、临床总体评分(d = 0.56;95% CI,0.44至0.68;P = 0.0001)和综合神经心理学测量(d = 0.27;95% CI,0.22至0.32;P = 0.0001)评估,喜得镇比安慰剂更有效。住院状态、每日剂量4毫克或更高以及血管性痴呆通常与更大的疗效相关。在可能患有阿尔茨海默病痴呆症的患者中,仅在五项试验中的综合神经心理学测量显示出显著疗效(d = 0.30;95% CI,0.16至0.44;P = 0.0001;且存在剂量反应关系,P = 0.001)。
总体而言,甲磺酸双氢麦角毒碱比安慰剂更有效。然而,在可能患有阿尔茨海默病痴呆症的患者中,其疗效充其量非常有限。剂量反应关系表明,潜在有效剂量可能高于目前批准的剂量。喜得镇疗效的具体情况仍未得到充分界定。